Prior work in tumor-bearing mice showed that the depletion of macrophages using anti-CSF1R antibodies abrogates hepatotoxicity observed when gemcitabine is administered 2 days after a CD40 agonist (21). The gene discussed is CSF1R; the disease is neoplasm.